AzTrials
AzTrials

NeoplasmsPhase 1NCT02964013

Study of Vibostolimab Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001) ( KEYVIBE-001)

A Phase 1 study testing vibostolimab, pembrolizumab and pemetrexed in people with Neoplasms, run by Merck Sharp & Dohme LLC.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This is a safety, efficacy, and pharmacokinetics (PK) study of vibostolimab (MK-7684) as monotherapy and in combination with pembrolizumab (MK-3475) or pembrolizumab plus pemetrexed and carboplatin in adults with metastatic solid tumors for which there is no available therapy that is expected to convey clinical… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Neoplasms
What is being tested?
vibostolimab, pembrolizumab and pemetrexed
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
474 participants
Where
No sites listed yet
Study dates
13 Dec 2016to 24 Jul 2024
Phase
Phase 1
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • For Part A participants enrolled prior to Amendment 7, must have a histologically or cytologically confirmed metastatic solid tumor for which there is no available therapy that is expected to convey clinical benefit
  • For Part A Japanese cohort added with Amendment 7: Must reside in Japan and be of Japanese descent and have adenocarcinoma of the stomach and/or gastric-esophageal junction (GEJ) that is considered inoperable and that has received, and progressed on, at least 1 prior chemotherapy regimen or human epidermal growth factor receptor 2 (HER2)/neu-targeted approved therapy (if HER2/neu-positive). In both cases, participants may be untreated or could have received and progressed on 1 prior regimen, but must not have received prior anti-PD-1/PD-L1 therapy
  • For Part A participants with non-small cell lung cancer (NSCLC) added with Amendment 7: Must have a histologically or cytologically confirmed diagnosis of stage IV (M1a or M1b per current American Joint Committee on Cancer criteria, edition 8) non-squamous NSCLC
  • For Part B China participants added with Amendment 12. Must have a histologically or cytologically confirmed metastatic solid tumor for which no more than 2 prior lines of therapy were administered and there is no available therapy that is expected to convey clinical benefit AND be Chinese from mainland China
  • For Parts A and B: Has histologically or cytologically confirmed metastatic solid tumor
  • Has measurable disease by Response Evaluation Criteria In Solid Tumors (RECIST)
Show all 11Show fewer
  • Has an Eastern Cooperative Oncology Group performance status of 0 to 1
  • Females must not be pregnant
  • Women of childbearing potential and male participants must agree to use adequate contraception for the course of the study
  • Has provided a tumor tissue sample (archival or newly obtained core or excisional biopsy of a tumor lesion)
  • For Chinese participants enrolled as part of Amendment 12. No tumor tissue samples will be collected

Who cannot join

  • Has had chemotherapy, radiation, biological cancer therapy or major surgery within 4 weeks prior to the first dose of study treatment
  • Has not recovered to Common Toxicity Criteria for Adverse Events Grade 1 or better from the adverse events due to cancer therapeutics administered more than 4 weeks prior to the first dose of study treatment
  • Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment
  • Has received previous treatment with another agent targeting the T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif (TIGIT) receptor
  • Has received previous treatment with an immunomodulatory agent (e.g., anti-programmed cell death 1, anti-programmed cell death ligand 1 or cytotoxic T-lymphocyte-associated protein 4) and was discontinued from that treatment due to a Grade 3 or higher immune-related adverse event
  • Is expected to require any other form of antineoplastic therapy while participating in the trial
Show all 22Show fewer
  • Is on chronic systemic steroid therapy in excess of replacement doses or on any other form of immunosuppressive medication
  • Has a history of a previous additional malignancy unless potentially curative treatment has been completed with no evidence of malignancy for 5 years
  • Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
  • Has an active autoimmune disease
  • Has an active infection requiring systemic treatment
  • Has interstitial lung disease
  • Has active or past history of (non-infectious) pneumonitis requiring steroids
  • Has symptomatic ascites or pleural effusion
  • Has previously had a hematopoetic stem cell transplant or solid organ transplant
  • Is known to be human immunodeficiency virus (HIV) positive and/or known to have active chronic or acute Hepatitis B or Hepatitis C
  • Has a known psychiatric and/or substance abuse disorder that would make it difficult for the participant to cooperate with the requirements of the trial
  • Is a regular user (including recreational use) of any illicit drugs at the time of providing documented informed consent, or has a recent history (within the last year) of substance abuse
  • Has received a live virus vaccine within 30 days prior to the first dose of study treatment
  • Has had hormonal cancer therapy (e.g., tamoxifen, leuprolide). within 4 weeks prior to the first dose of study treatment
  • For Part A participants with NSCLC added with Amendment 7: Is unable to interrupt aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) other than an aspirin dose ≤1.3 gram per day for a 5-day period (8-day period for long-acting agents, such as piroxicam)
  • For Part A participants with NSCLC added with Amendment 7: Is unable or unwilling to take folic acid or Vitamin B12 supplementation

About this study

Official title: A Phase 1 Trial of MK-7684 as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

This is a safety, efficacy, and pharmacokinetics (PK) study of vibostolimab (MK-7684) as monotherapy and in combination with pembrolizumab (MK-3475) or pembrolizumab plus pemetrexed and carboplatin in adults with metastatic solid tumors for which there is no available therapy that is expected to convey clinical benefit. Part A of this study is a dose escalation and confirmation phase to estimate the recommended Phase 2 dose (RPTD) for vibostolimab monotherapy or in combination with pembrolizumab, pemetrexed, and carboplatin. Part A will also evaluate the anti-tumor activity of vibostolimab in combination with pembrolizumab plus pemetrexed and carboplatin in participants with non-small cell lung cancer (NSCLC) and vibostolimab (at two dose levels) in combination with pembrolizumab in Japanese participants with gastric cancer. Part B will evaluate the anti-tumor activity of vibostolimab at the RPTD when used as monotherapy and in combination with pembrolizumab in participants with advanced solid tumors in a non-randomized study design. Part B will also evaluate 2 doses of vibostolimab in combination with pembrolizumab in participants with programmed death 1 (PD-1) treatment naïve cancer using a 1:1 randomized study design. Part B is expanded with Amendment 11 to include an additional arm that will compare the safety and PK of a fixed dose of pembrolizumab/vibostolimab coformulation (MK-7684A) to vibostolimab in combination with pembrolizumab administered as separate intravenous infusions. Part A is expanded with Amendment 12 to include an additional arm that will compare the safety and PK of vibostolimab plus pembrolizumab plus the investigator's choice of platinum agent (carboplatin or cisplatin), and etoposide. Part B is expanded with Amendment 12 to include evaluation of efficacy of vibostolimab plus pembrolizumab plus the investigator's choice of platinum agent (carboplatin or cisplatin), and etoposide and efficacy of pembrolizumab/vibostolimab coformulation in participants from mainland China. The primary hypotheses are that vibostolimab administered as monotherapy or in combination with pembrolizumab is safe and tolerable when administered at the RPTD and that pembrolizumab/vibostolimab coformulation is safe and tolerable when administered as a fixed dose.

Conditions
Neoplasms
Being tested
vibostolimab, pembrolizumab, pemetrexed, carboplatin, pembrolizumab/vibostolimab coformulation
Keywords
Programmed Cell Death Receptor 1 (PD-1), Programmed Cell Death Receptor Ligand 1 (PD-L1), Programmed Cell Death Receptor Ligand 2 (PD-L2), PD-1, PDL1, PD-L1, PD-L2
Medical subject headings
Neoplasms, Parkinson Disease 4, Autosomal Dominant Lewy Body

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • vibostolimabBiological

    Also called MK-7684

    Administered as an intravenous (IV) infusion on Day 1 of 21-day infusion Cycles 1-35

  • pembrolizumabBiological

    Also called KEYTRUDA®, MK-3475

    Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-35

  • pemetrexedDrug

    Also called ALIMTA®

    Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-35

  • carboplatinDrug

    Also called PARAPLATIN®

    Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-4

  • pembrolizumab/vibostolimab coformulationBiological

    Also called MK-7684A

    Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-35

  • cisplatinDrug

    Also called PLATINOL-AQ®

    Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-4

  • etoposideDrug

    Also called ETOPOPHOS®

    Administered as an IV infusion on Days 1-3 of 21-day infusion Cycles 1-4

Study groups in NCT02964013
Study groupRoleWhat they receive
vibostolimabExperimentalDuring an initial dose evaluation phase, participants will receive Dose A, B, C, D, E, or F of vibostolimab on Day 1 of each 21-day infusion cycle (for a maximum of 35 cycles) until the RPTD has been established. The RPTD will be established based on the number of dose limiting toxicities (DLTs) at each dose level. Once the RPTD is established, participants will continue receiving the RPTD of vibostolimab on Day 1 of each 21-day infusion cycle until the 35-cycle limit is reached.
Receives: Biological: vibostolimab
vibostolimab + pembrolizumabExperimentalDuring an initial dose evaluation phase, participants will receive Dose A, B, C, D, E, or F of vibostolimab in combination with 200 mg pembrolizumab on Day 1 of each 21-day infusion cycle (for a maximum of 35 cycles) until the RPTD of vibostolimab has been established. The RPTD will be established based on the number of DLTs at each dose level. Once the RPTD of vibostolimab is established, participants will continue receiving the RPTD of vibostolimab in combination with 200 mg pembrolizumab on Day 1 of each 21-day infusion cycle until the 35-cycle limit is reached.
Receives: Biological: vibostolimab; Biological: pembrolizumab
Advanced solid tumor cohortExperimentalParticipants will receive the RPTD of vibostolimab monotherapy or the RPTD of vibostolimab in combination with 200 mg pembrolizumab on Day 1 of each 21-day infusion cycle until the 35-cycle limit is reached.
Receives: Biological: vibostolimab; Biological: pembrolizumab
Randomized dose 1 comparison cohortExperimentalParticipants will be randomized to receive a fixed dose (Dose 1) of vibostolimab in combination with 200 mg pembrolizumab on Day 1 of each 21-day infusion cycle until the 35-cycle limit is reached.
Receives: Biological: vibostolimab; Biological: pembrolizumab
Randomized dose 2 comparison cohortExperimentalParticipants will be randomized to receive a fixed dose (Dose 2) of vibostolimab in combination with 200 mg pembrolizumab on Day 1 of each 21-day infusion cycle until the 35-cycle limit is reached.
Receives: Biological: vibostolimab; Biological: pembrolizumab
vibostolimab +pembrolizumab+pemetrexed+carboplatinExperimentalParticipants will receive a fixed dose of vibostolimab in combination with 200 mg pembrolizumab, 500 mg/m^2 pemetrexed, and Area Under Curve (AUC) 5 mg/mL/min carboplatin on Day 1 of each 21-day infusion cycle for up to 4 cycles followed by maintenance therapy with a fixed dose of vibostolimab in combination with 200 mg pembrolizumab and 500 mg/m^2 pemetrexed on Day 1 of each 21-day infusion cycle for up to an additional 31 cycles.
Receives: Biological: vibostolimab; Biological: pembrolizumab; Drug: pemetrexed; Drug: carboplatin
vibostolimab Dose 1 Japanese cohortExperimentalJapanese participants will be randomized to receive a fixed dose (Dose 1) of vibostolimab in combination with 200 mg pembrolizumab on Day 1 of each 21-day infusion cycle until the 35-cycle limit is reached.
Receives: Biological: vibostolimab; Biological: pembrolizumab
vibostolimab Dose 2 Japanese cohortExperimentalJapanese participants will be randomized to receive a fixed dose (Dose 2) of vibostolimab in combination with 200 mg pembrolizumab on Day 1 of each 21-day infusion cycle until the 35-cycle limit is reached.
Receives: Biological: vibostolimab; Biological: pembrolizumab
pembrolizumab/vibostolimab coformulationExperimentalParticipants will receive a fixed dose of pembrolizumab/vibostolimab coformulation, consisting of 200 mg of pembrolizumab + 200 mg vibostolimab, on Day 1 of each 21-day infusion cycle for up to 35 cycles.
Receives: Biological: pembrolizumab/vibostolimab coformulation
vibostolimab+pembrolizumab+carboplatin OR cisplatin+etoposideExperimentalParticipants will receive 200 mg vibostolimab in combination with 200 mg pembrolizumab, plus the investigator's choice of Area Under Curve (AUC) 5 mg/mL/min carboplatin OR 75 mg/m^2 cisplatin on Day 1 of each 21-day cycle plus 100 mg/m^2/day etoposide on Days 1-3 of each 21-day cycle for up to 4 cycles. Maintenance therapy with 200 mg vibostolimab in combination with 200 mg pembrolizumab on Day 1 of each 21-day cycle will continue for up to an additional 31 cycles. A participant will be allowed to switch from cisplatin to carboplatin in the event of an adverse event (AE), ineligibility for further cisplatin therapy, and/or the investigator considers switching to carboplatin to be in the best interest of the participant.
Receives: Biological: vibostolimab; Biological: pembrolizumab; Drug: carboplatin; Drug: cisplatin; Drug: etoposide
pembrolizumab/vibostolimab coformulation China cohortExperimentalParticipants from mainland China will receive a fixed dose of pembrolizumab/vibostolimab coformulation, consisting of 200 mg of pembrolizumab + 200 mg vibostolimab, on Day 1 of each 21-day infusion cycle for up to 35 cycles.
Receives: Biological: pembrolizumab/vibostolimab coformulation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of Participants With Dose Limiting Toxicities (DLTs) up to 24 Months

    A DLT is defined as an event with toxicity including the type, severity, time of onset, time of resolution, and the probable association with study treatment that are not due to pre-existing conditions as defined by the Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE4.0).

    Measured: Up to 24 Months

  2. Number of Participants Who Experienced At Least One Adverse Event (AE)

    An AE is defined as any untoward medical occurrence in a participant or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol specified procedure, whether or not considered related to the medicinal product or protocol specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event.

    Measured: Up to 28 Months

  3. Number of Participants Who Discontinued Study Treatment Due to an AE

    An AE is defined as any untoward medical occurrence in a participant or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol specified procedure, whether or not considered related to the medicinal product or protocol specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event.

    Measured: Up to 24 Months

Secondary outcomes (24)

  1. Overall Response Rate (ORR) in Participants in Vibostolimab Dose Escalation Phase Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

    ORR is the percentage of participants who experience complete response (CR: disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions) at any time during the trial using RECIST, version 1.1 as assessed by investigator review. Results for participants treated with vibostolimab dose escalation are presented.

    Measured: Up to 24 Months

  2. ORR in Participants With Programmed Death 1 (PD-1) Refractory Non-small Cell Lung Cancer (NSCLC) Per RECIST 1.1

    ORR is the percentage of participants who experience complete response (CR: disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions) at any time during the trial using RECIST, version 1.1 as assessed by investigator review. Results for participants with PD-1 refractory NSCLC treated with 200 or 210 mg vibostolimab in dose escalation as well as dose expansion phases are presented.

    Measured: Up to 24 Months

  3. ORR in Participants With PD-1 Naive NSCLC Per RECIST 1.1

    ORR is the percentage of participants who experience complete response (CR: disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions) at any time during the trial using RECIST, version 1.1 as assessed by investigator review. Results for participants with PD-1 naive NSCLC treated with pembrolizumab and 200 mg vibostolimab from both the dose escalation and expansion phases are presented.

    Measured: Up to 24 Months

  4. ORR in Participants With Extensive-stage Small Cell Lung Cancer (ES-SCLC) Per RECIST 1.1

    ORR is the percentage of participants who experience complete response (CR: disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions) at any time during the trial using RECIST, version 1.1 as assessed by investigator review. Participants with ES-SCLC treated with vibostolimab in combination with pembrolizumab, carboplatin or cisplatin, and etoposide were analyzed.

    Measured: Up to 24 Months

  5. ORR in Participants With PD-1 Naive Ovarian Cancer Per RECIST 1.1

    ORR is the percentage of participants who experience complete response (CR: disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions) at any time during the trial using RECIST, version 1.1 as assessed by investigator review. Participants with PD-1 naive ovarian cancer treated with pembrolizumab and vibostolimab dose escalation or MK-7984A were analyzed.

    Measured: Up to 24 Months

  6. ORR in Participants With PD-1 Naive Cervical Cancer Per RECIST 1.1

    ORR is the percentage of participants who experience complete response (CR: disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions) at any time during the trial using RECIST, version 1.1 as assessed by investigator review. Results for participants with PD-1 naive cervical cancer treated with pembrolizumab and either 200 mg or 700 mg vibostolimab are presented.

    Measured: Up to 24 Months

  7. Area Under the Curve From Time 0 to 21 Days Postdose (AUC 0-21 Days) of Plasma Vibostolimab Following Treatment With Increasing Amounts of Vibostolimab Monotherapy or Vibostolimab With 200 mg Pembrolizumab

    Blood samples were collected from participants during cycle 1 and cycle 4 of treatment (Cycle length is 21 days) in order to determine the AUC 0-21 days of plasma vibostolimab, Only results from participants treated with increasing amounts of vibostolimab monotherapy or vibostolimab combined with 200 mg pembrolizumab are presented; whereas other treatment groups were not analyzed. Due to terminal fitting issue, non-calculable AUC0-21 days was replaced with AUClast for a few participants.

    Measured: Cycle 1, Cycle 4: Day 1 pre-dose, 0.5, and 2 hours post-dose; once daily on Days 2, 3, 5, 8, 15 and 22.

  8. AUC 0-21 Days of Plasma Vibostolimab Following Treatment With 200 mg Vibostolimab Combined With Various Other Treatments

    Blood samples were collected from participants during cycle 1 and cycle 4 of treatment (Cycle length is 21 days) following treatment with 200 mg vibostolimab in order to determine the AUC 0-21 days of plasma vibostolimab, Due to terminal fitting issue, non-calculable AUC0-21 days was replaced with AUClast for a few participants.

    Measured: Cycle 1, Cycle 4: Day 1 pre-dose, 0.5 and 2 hours post-dose; once daily on Days 2, 3, 5, 8, 15 and 22

  9. AUC 0-21 Days of Plasma Pembrolizumab Following Treatment With Increasing Amounts of Vibostolimab With 200 mg Pembrolizumab

    Blood samples were collected from participants during cycle 1 and cycle 4 of treatment (Cycle length is 21 days) in order to determine the AUC 0-21 days of plasma vibostolimab, Only results from participants treated with increasing amounts of vibostolimab combined with 200 mg pembrolizumab are presented; whereas other treatment groups were not analyzed. Due to terminal fitting issue, non-calculable AUC0-21 days was replaced with AUClast for a few participants.

    Measured: Cycle 1, Cycle 4: Day 1 pre-dose, 0.5 and 2 hours post-dose; once daily on Days 2, 3, 5, 8, 15 and 22

  10. AUC 0-21 Days of Plasma Pembrolizumab Following Treatment With 200 mg Vibostolimab and 200 mg Pembrolizumab Combined With Various Other Treatments

    Blood samples were collected from participants during cycle 1 and cycle 4 of treatment (Cycle length is 21 days) following treatment with 200 mg vibostolimab and 200 mg pembrolizumab in order to determine the AUC 0-21 days of plasma pembrolizumab. Due to terminal fitting issue, non-calculable AUC0-21 days was replaced with AUClast for a few participants.

    Measured: Cycle 1, Cycle 4: Day 1 pre-dose, 0.5 and 2 hours post-dose; once daily on Days 2, 3, 5, 8, 15 and 22

  11. Maximum Plasma Concentration (Cmax) of Plasma Vibostolimab Following Treatment With Increasing Amounts of Vibostolimab Monotherapy or Vibostolimab With 200 mg Pembrolizumab

    Blood samples were collected from participants during cycle 1 and cycle 4 of treatment (Cycle length is 21 days) in order to determine the Cmax of plasma vibostolimab, Only results from participants treated with increasing amounts of vibostolimab monotherapy or vibostolimab combined with 200 mg pembrolizumab are presented; whereas other treatment groups were not analyzed.

    Measured: Cycle 1, Cycle 4: Day 1 pre-dose, 0.5 and 2 hours post-dose; once daily on Days 2, 3, 5, 8, 15 and 22

  12. Cmax of Plasma Vibostolimab Following Treatment With 200 mg Vibostolimab Combined With Various Other Treatments

    Blood samples were collected from participants during cycle 1 and cycle 4 of treatment (Cycle length is 21 days) following treatment with 200 mg vibostolimab in order to determine the Cmax of plasma vibostolimab,

    Measured: Cycle 1, Cycle 4: Day 1 pre-dose, 0.5 and 2 hours post-dose; once daily on Days 2, 3, 5, 8, 15 and 22

  13. Cmax of Plasma Pembrolizumab Following Treatment With Increasing Amounts of Vibostolimab With 200 mg Pembrolizumab

    Blood samples were collected from participants during cycle 1 and cycle 4 of treatment (Cycle length is 21 days) in order to determine the Cmax of plasma vibostolimab, Only results from participants treated with increasing amounts of vibostolimab combined with 200 mg pembrolizumab are presented; whereas other treatment groups were not analyzed.

    Measured: Cycle 1, Cycle 4: Day 1 pre-dose, 0.5 and 2 hours post-dose; once daily on Days 2, 3, 5, 8, 15 and 22

  14. Cmax of Plasma Pembrolizumab Following Treatment With 200 mg Vibostolimab and 200 mg Pembrolizumab Combined With Various Other Treatments

    Blood samples were collected from participants during cycle 1 and cycle 4 of treatment (Cycle length is 21 days) following treatment with 200 mg vibostolimab and 200 mg pembrolizumab in order to determine the Cmax of plasma pembrolizumab.

    Measured: Cycle 1, Cycle 4: Day 1 pre-dose, 0.5 and 2 hours post-dose; once daily on Days 2, 3, 5, 8, 15 and 22

  15. Trough Concentration (Ctrough) of Plasma Vibostolimab Following Treatment With Increasing Amounts of Vibostolimab Monotherapy or Vibostolimab With 200 mg Pembrolizumab

    Blood samples were collected from participants during cycle 1 and cycle 4 of treatment (Cycle length is 21 days) in order to determine the Ctrough of plasma vibostolimab, Only results from participants treated with increasing amounts of vibostolimab monotherapy or vibostolimab combined with 200 mg pembrolizumab are presented; whereas other treatment groups were not analyzed.

    Measured: Cycle 1, Cycle 4: Day 1 pre-dose, 0.5 and 2 hours post-dose; once daily on Days 2, 3, 5, 8, 15 and 22

  16. Ctrough of Plasma Vibostolimab Following Treatment With 200 mg Vibostolimab Combined With Various Other Treatments

    Blood samples were collected from participants during cycle 1 and cycle 4 of treatment (Cycle length is 21 days) following treatment with 200 mg vibostolimab in order to determine the Ctrough of plasma vibostolimab,

    Measured: Cycle 1, Cycle 4: Day 1 pre-dose, 0.5 and 2 hours post-dose; once daily on Days 2, 3, 5, 8, 15 and 22

  17. Ctrough of Plasma Pembrolizumab Following Treatment With Increasing Amounts of Vibostolimab With 200 mg Pembrolizumab

    Blood samples were collected from participants during cycle 1 and cycle 4 of treatment (Cycle length is 21 days) in order to determine the Ctrough of plasma vibostolimab, Only results from participants treated with increasing amounts of vibostolimab combined with 200 mg pembrolizumab are presented; whereas other treatment groups were not analyzed.

    Measured: Cycle 1, Cycle 4: Day 1 pre-dose, 0.5 and 2 hours post-dose; once daily on Days 2, 3, 5, 8, 15 and 22

  18. Ctrough of Plasma Pembrolizumab Following Treatment With 200 mg Vibostolimab and 200 mg Pembrolizumab Combined With Various Other Treatments

    Blood samples were collected from participants during cycle 1 and cycle 4 of treatment (Cycle length is 21 days) following treatment with 200 mg vibostolimab and 200 mg pembrolizumab in order to determine the Ctrough of plasma pembrolizumab.

    Measured: Cycle 1, Cycle 4: Day 1 pre-dose, 0.5 and 2 hours post-dose; once daily on Days 2, 3, 5, 8, 15 and 22

  19. Half Life (t1/2)) of Plasma Vibostolimab Following Treatment With Increasing Amounts of Vibostolimab Monotherapy or Vibostolimab With 200 mg Pembrolizumab

    Blood samples were collected from participants during cycle 1 and cycle 4 of treatment (Cycle length is 21 days) in order to determine the t1/2 of plasma vibostolimab, Only results from participants treated with increasing amounts of vibostolimab monotherapy or vibostolimab combined with 200 mg pembrolizumab are presented; whereas other treatment groups were not analyzed.

    Measured: Cycle 1, Cycle 4: Day 1 pre-dose, 0.5 and 2 hours post-dose; once daily on Days 2, 3, 5, 8, 15 and 22

  20. t1/2 of Plasma Vibostolimab Following Treatment With 200 mg Vibostolimab Combined With Various Other Treatments

    Blood samples were collected from participants during cycle 1 and cycle 4 of treatment (Cycle length is 21 days) following treatment with 200 mg vibostolimab in order to determine thet1/2 of plasma vibostolimab,

    Measured: Cycle 1, Cycle 4: Day 1 pre-dose, 0.5 and 2 hours post-dose; once daily on Days 2, 3, 5, 8, 15 and 22

  21. t1/2 of Plasma Pembrolizumab Following Treatment With Increasing Amounts of Vibostolimab With 200 mg Pembrolizumab

    Blood samples were collected from participants during cycle 1 and cycle 4 of treatment (Cycle length is 21 days) in order to determine the t1/2 of plasma vibostolimab, Only results from participants treated with increasing amounts of vibostolimab combined with 200 mg pembrolizumab are presented; whereas other treatment groups were not analyzed.

    Measured: Cycle 1, Cycle 4: Day 1 pre-dose, 0.5 and 2 hours post-dose; once daily on Days 2, 3, 5, 8, 15 and 22

  22. t1/2 of Plasma Pembrolizumab Following Treatment With 200 mg Vibostolimab and 200 mg Pembrolizumab Combined With Various Other Treatments

    Blood samples were collected from participants during cycle 1 and cycle 4 of treatment (Cycle length is 21 days) following treatment with 200 mg vibostolimab and 200 mg pembrolizumab in order to determine the t1/2 of plasma pembrolizumab.

    Measured: Cycle 1, Cycle 4: Day 1 pre-dose, 0.5 and 2 hours post-dose; once daily on Days 2, 3, 5, 8, 15 and 22

  23. Number of Participants Experiencing a Dose-Limiting Toxicity (DLT) at the End of Cycle 1

    A DLT is defined as an event with toxicity including the type, severity, time of onset, time of resolution, and the probable association with study treatment that are not due to pre-existing conditions as defined by CTCAE 4.0

    Measured: At the end of Cycle 1 (up to 21 days)

  24. Rate of Progression Free Survival (PFS) Per RECIST 1.1 at 6 Months

    The progression free survival (PFS) rate is the percentage of participants who achieve PFS as estimated by the Kaplan-Meier method. PFS is the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first using RECIST, version 1.1 as assessed by investigator review. PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. Rate of PFS was planned and therefore only reported for participants treated with vibostolimab in combination with pembrolizumab, carboplatin or cisplatin, and etoposide. Other treatment groups were not analyzed.

    Measured: 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Nov 2016 (estimated)
  2. Study start13 Dec 2016
  3. Primary completion24 Jul 2024
  4. Study completion24 Jul 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
474 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02964013
Sponsor's protocol ID
7684-001
Other IDs
MK-7684-001, 194809, KEYVIBE-001
Status last verified
Sep 2025
First submitted
11 Nov 2016
Last updated
14 Oct 2025
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Publications

  • Niu J, Maurice-Dror C, Lee DH, Kim DW, Nagrial A, Voskoboynik M, Chung HC, Mileham K, Vaishampayan U, Rasco D, Golan T, Bauer TM, Jimeno A, Chung V, Chartash E, Lala M, Chen Q, Healy JA, Ahn MJ. First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆. Ann Oncol. 2022 Feb;33(2):169-180. doi: 10.1016/j.annonc.2021.11.002. Epub 2021 Nov 18.

    PubMed 34800678

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing vibostolimab, pembrolizumab and pemetrexed in people with Neoplasms, run by Merck Sharp & Dohme LLC.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 11 inclusion and 22 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 14 Oct 2025. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 14 Oct 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of Participants With Dose Limiting Toxicities (DLTs) up to 24 Months (time frame: Up to 24 Months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02964013, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Oct 2025.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in